Markus Thomas

3.4k total citations
28 papers, 2.1k citations indexed

About

Markus Thomas is a scholar working on Molecular Biology, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Markus Thomas has authored 28 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Markus Thomas's work include Angiogenesis and VEGF in Cancer (20 papers), Glycosylation and Glycoproteins Research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Markus Thomas is often cited by papers focused on Angiogenesis and VEGF in Cancer (20 papers), Glycosylation and Glycoproteins Research (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Markus Thomas collaborates with scholars based in Germany, Switzerland and United States. Markus Thomas's co-authors include Hellmut G. Augustin, Christian Klein, Jörg T. Regula, Hubert Kettenberger, Wolfgang Schaefer, Karoline Kruse, Ulrike Fiedler, Jürgen Schanzer, Claudio Sustmann and Rebecca Croasdale and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Markus Thomas

27 papers receiving 2.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Markus Thomas 1.4k 576 520 409 351 28 2.1k
Douglas Armellino 1.3k 1.0× 444 0.8× 738 1.4× 401 1.0× 247 0.7× 18 2.3k
Yen‐Ming Hsu 1.1k 0.8× 242 0.4× 377 0.7× 799 2.0× 1.5k 4.3× 36 3.1k
Marya F. McCarty 2.0k 1.4× 122 0.2× 1.1k 2.2× 869 2.1× 436 1.2× 37 3.0k
Yoshiyuki Abe 1.4k 1.0× 389 0.7× 1.0k 1.9× 741 1.8× 419 1.2× 137 2.9k
Takashi Fukutomi 883 0.6× 444 0.8× 1.2k 2.4× 1.2k 2.8× 154 0.4× 163 3.1k
Niina Veitonmäki 807 0.6× 211 0.4× 578 1.1× 394 1.0× 446 1.3× 22 1.8k
Bing Liao 670 0.5× 310 0.5× 371 0.7× 444 1.1× 135 0.4× 71 1.9k
Otto Sánchez 1.3k 1.0× 114 0.2× 909 1.7× 661 1.6× 197 0.6× 41 2.5k
J. P. Johnson 759 0.5× 300 0.5× 561 1.1× 229 0.6× 686 2.0× 31 2.0k
Gregor Krings 1.2k 0.9× 113 0.2× 825 1.6× 813 2.0× 246 0.7× 62 2.8k

Countries citing papers authored by Markus Thomas

Since Specialization
Citations

This map shows the geographic impact of Markus Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Thomas more than expected).

Fields of papers citing papers by Markus Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Thomas. The network helps show where Markus Thomas may publish in the future.

Co-authorship network of co-authors of Markus Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Thomas. A scholar is included among the top collaborators of Markus Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Thomas. Markus Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Singhal, Mahak, Carolin Mogler, Nicolas Gengenbacher, et al.. (2020). Tumor Cell–Derived Angiopoietin-2 Promotes Metastasis in Melanoma. Cancer Research. 80(12). 2586–2598. 30 indexed citations
2.
Scheuer, Werner, Markus Thomas, P Hanke, et al.. (2016). Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2. mAbs. 8(3). 562–573. 19 indexed citations
3.
Boult, Jessica K.R., Markus Thomas, Astrid Koehler, et al.. (2016). Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. British Journal of Cancer. 115(6). 691–702. 14 indexed citations
4.
Wong, Bernice H., Dachuan Huang, Jing Tan, et al.. (2015). Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma. Cancer Investigation. 33(8). 378–386. 11 indexed citations
5.
Felcht, Moritz & Markus Thomas. (2015). Angiogenesis in malignant melanoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 13(2). 125–135. 29 indexed citations
6.
Nowak, Radosław P., Erica Lorenzon, Markus Thomas, et al.. (2015). An integrated approach to quantitative modelling in angiogenesis research. Journal of The Royal Society Interface. 12(110). 20150546–20150546. 19 indexed citations
7.
Srivastava, Kshitij, Junhao Hu, Claudia Korn, et al.. (2014). Postsurgical Adjuvant Tumor Therapy by Combining Anti-Angiopoietin-2 and Metronomic Chemotherapy Limits Metastatic Growth. Cancer Cell. 26(6). 880–895. 113 indexed citations
8.
Kienast, Yvonne, Christian Klein, Werner Scheuer, et al.. (2013). Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy. Clinical Cancer Research. 19(24). 6730–6740. 143 indexed citations
9.
Schiller, Christian, Julia J. Griese, Sabine Imhof-Jung, et al.. (2013). Crystal Structure of an Anti-Ang2 CrossFab Demonstrates Complete Structural and Functional Integrity of the Variable Domain. PLoS ONE. 8(4). e61953–e61953. 25 indexed citations
10.
Benest, Andrew V., Karoline Kruse, Soniya Savant, et al.. (2013). Angiopoietin-2 Is Critical for Cytokine-Induced Vascular Leakage. PLoS ONE. 8(8). e70459–e70459. 132 indexed citations
11.
12.
Klein, Christian, Claudio Sustmann, Markus Thomas, et al.. (2012). Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs. 4(6). 653–663. 157 indexed citations
13.
Lehmann, Christian H.K., et al.. (2012). Established breast cancer stem cell markers do not correlate with in vivo tumorigenicity of tumor-initiating cells. International Journal of Oncology. 41(6). 1932–1942. 30 indexed citations
14.
15.
Schaefer, Wolfgang, Jörg T. Regula, Monika Bähner, et al.. (2011). Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proceedings of the National Academy of Sciences. 108(27). 11187–11192. 334 indexed citations
16.
Rennel, Emma, Jörg T. Regula, Steven J. Harper, et al.. (2011). A Human Neutralizing Antibody Specific to Ang‐2 Inhibits Ocular Angiogenesis. Microcirculation. 18(7). 598–607. 27 indexed citations
17.
Thomas, Markus, Moritz Felcht, Karoline Kruse, et al.. (2010). Angiopoietin-2 Stimulation of Endothelial Cells Induces αvβ3 Integrin Internalization and Degradation. Journal of Biological Chemistry. 285(31). 23842–23849. 82 indexed citations
18.
Nasarre, Patrick, Markus Thomas, Karoline Kruse, et al.. (2009). Host-Derived Angiopoietin-2 Affects Early Stages of Tumor Development and Vessel Maturation but Is Dispensable for Later Stages of Tumor Growth. Cancer Research. 69(4). 1324–1333. 140 indexed citations
19.
Helfrich, Iris, Lutz Edler, Antje Sucker, et al.. (2009). Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma. Clinical Cancer Research. 15(4). 1384–1392. 152 indexed citations
20.
Thomas, Markus & Hellmut G. Augustin. (2009). The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 12(2). 125–137. 312 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Douglas Armellino Breakdown of academic impact, for papers by Yen‐Ming Hsu Breakdown of academic impact, for papers by Marya F. McCarty Breakdown of academic impact, for papers by Yoshiyuki Abe Breakdown of academic impact, for papers by Takashi Fukutomi Breakdown of academic impact, for papers by Niina Veitonmäki Breakdown of academic impact, for papers by Bing Liao Breakdown of academic impact, for papers by Otto Sánchez Breakdown of academic impact, for papers by J. P. Johnson Breakdown of academic impact, for papers by Gregor Krings
Rankless by CCL
2026